Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Carcinoid Tumor 3Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Neoplasm Metastasis 1Gigantism 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Flushing 1Endocrine Tumors 1Diarrhea 1Acromegaly 1

Interventions

Oxaliplatin 4Leucovorin 4Irinotecan 4Fluorouracil 4Capecitabine 3Bevacizumab 3cobimetinib 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Panitumumab 2Magnetic Resonance Spectroscopy 2Ketamine 2Hydroxychloroquine 2Cyclophosphamide 2Cisplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sodium thiosulfate 1rucaparib 1romiplostim 1rilotumumab 1regorafenib 1pralsetinib 1ponatinib 1pembrolizumab 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Neoplasms × lanreotide × Clear all
NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡